Singh Nikhilesh N 4

4 · Transcept Pharmaceuticals Inc · Filed Jan 19, 2010

Form 4

Period: 2010-01-14

SVP & Chief Scientific Officer

Transactions

Award
Employree Stock Option (right to buy)
2010-01-14+47,300→ 47,300 total
Exercise: $8.21Exp: 2020-01-14→ Common Stock (47,300 underlying)
Award
Employee Stock Option (right to buy)
2010-01-14+24,100→ 24,100 total
Exercise: $8.21Exp: 2020-01-14→ Common stock (24,100 underlying)

Holdings

Footnotes (6)

[F1]This total includes 1,354 shares purchased on November 30, 2009 under the 2009 Employee Stock Purchase Plan.
[F2]Shares held directly by the Reporting Person's spouse.
[F3]Shares held directly by the Singh Family Trust (the "Family Trust") for which Reporting Person's spouse serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Family Trust except to the extent of his pecuniary interest therein.
[F4]Shares held directly by the Nikhilesh and Nikki Singh Revocable Trust (the "Revocable Trust") for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of the shares held by the Revocable Trust except to the extent of his pecuniary interest therein.
[F5]The option vests in forty-eight equal monthly installments beginning February 14, 2010.
[F6]Fifty percent of the option vests upon approval by the U.S. Food and Drug Administration of Intermezzo(R) and the remaining fifty percent vests on the first anniversary of any such approval; provided in each case, such approval occurs no later than January 14, 2012.

Documents

1 file